Good morning. My name is Ruel and I will be your conference operator today. At this time, I would like to welcome everyone to Avantor's Third Quarter 2021 Earnings Results Conference Call. I will now turn the call over to Tommy Thomas, Vice President of Investor Relations. Mr. Thomas, you may begin the conference.

Good morning. Thank you for joining us today. Our speakers today are; Michael Stubblefield, President and Chief Executive Officer; and Tom Szlosek, Executive Vice President and Chief Financial Officer. The press release and a presentation accompanying this call are available on our Investor Relations website at ir.avantorsciences.com. A replay of this webcast will also be made available on our website after the call. Following our prepared remarks we will open the line for questions. During this call we will be making some forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties including those set forth in our SEC filings. Actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made. We do not assume any obligation to update these forward-looking statements whether as a result of new information, future events and developments or otherwise. This call will include a discussion of non-GAAP measures. A reconciliation of these non-GAAP measures can be found in the appendix to the presentation. With that I will now turn the call over to Michael. Michael?

Thanks Tommy and good morning, everyone. I appreciate you joining us today. I'm starting on Slide 3. By now you've seen our press release highlighting Avantor's third quarter results which reflect strong business momentum across our end markets and our team's continued track record of execution. We achieved 10.2% organic revenue growth in the quarter including a core growth rate of 8.5% and COVID tailwinds of approximately 1.7%. The COVID tailwinds were principally driven by our vaccine-related offerings. In addition to delivering double-digit organic top line results we grew adjusted EBITDA nearly 26%, resulting in EBITDA margin expansion of approximately 180 basis points. Adjusted EPS grew 48% to $0.35 per share. In September, we announced a definitive agreement to acquire Masterflex, a leading global manufacturer of peristaltic pumps and aseptic single-use fluid transfer technologies, expanding our proprietary single-use offering for bioproduction. We have since received all required regulatory clearances, have secured the necessary financing, and intend to close the transaction in short order. I will share more details about the transaction in a moment. We are committed to our role as a leader in life-changing science and remain focused on driving innovation and growth with investments in capabilities and capacity. This quarter, we advanced several expansion initiatives including our production capabilities for key chemicals used in upstream and downstream applications in the bioproduction workflow. We also advanced our hydration expansion strategy and recently opened a new European single-use facility in the Netherlands. Additionally, demonstrating our commitment to helping scientists realize the potential of breakthroughs through innovation, we announced a commercial agreement with Oxford Nanopore Technologies, a market-leading manufacturer of next-generation sequencing instruments, kits, and consumables. The agreement combines the breadth and depth of Avantor's global laboratory customer relationships across all of our end markets with the sequencing technology from Oxford Nanopore. It will provide scientists broader access to Oxford Nanopore's portable real-time nanopore sequencing device, along with associated consumables and reagents through Avantor's channel. Looking ahead, we believe our role in the innovation ecosystem positions us for continued business momentum. We expect our core business to remain strong in the fourth quarter and are once again raising our guidance for the full year. Tom will share details on this in a few minutes. During our recent Investor Day, we described how our distinctive capabilities set us apart from our competitors and position us for long-term sustainable growth. Our third quarter results prove the strength of our business and how our products and services enable scientific breakthroughs. We are in the process of finalizing our 2022 operating plan and anticipate delivering another outstanding year in line with our long-term targets. We will share more details with you as part of our fourth quarter earnings call early next year. Moving on to slide 4. I'd like to reiterate some of the highlights from our recent announcement about our pending acquisition of Masterflex. Masterflex will further strengthen our single-use offering for the high-growth biopharma end market. For more than 50 years, Masterflex has been providing industry-leading fluid transfer technologies that play a central role in biopharma research and production workflows. Masterflex's technologies are relevant across all established and emerging biopharma platforms including monoclonal antibodies, cell and gene therapy and mRNA, and support both vaccine and therapy manufacturing including COVID-19. More than 80% of Masterflex's revenue is concentrated in biopharma, giving us access to a $5 billion addressable market that is growing high double-digits and provides us a fully integrated solution for managing aseptic fluid transfer throughout the bioproduction workflow. The single-use fluid transfer space is an area of significant growth for Avantor supported by the expansion of our facilities and our previously announced acquisition of RIM Bio. Our single-use platform has been a key organic revenue driver of bioproduction sales to date and we see this acquisition as a further accelerator of our overall organic revenue growth rate. This transaction meets both our qualitative and quantitative acquisition criteria and is a great example of our M&A strategy in action. Our customers will benefit from our fully integrated aseptic fluid transfer solution throughout the bioproduction workflow and our financial profile will be enhanced by Masterflex's double-digit revenue growth and proprietary gross margins. As I mentioned, we expect to close this transaction in short order and are looking forward to welcoming the Masterflex team to the Avantor family. Turning to slide 5. I'd like to summarize our third quarter financial results. Revenues increased 10.2% on an organic basis and 14.3% on a reported basis including the impacts of foreign currency exchange tailwinds in the Ritter and RIM Bio acquisitions. All regions and all product groups experienced strong organic growth. Overall performance was driven by our biopharma end market growing high-teens with nearly 26% growth in bioproduction. We also experienced high single-digit growth in the Advanced Technologies and applied materials end market for the second consecutive quarter. COVID tailwinds contributed about 1.7% to our organic growth with the largest driver being proprietary materials and consumables sales to support the production of COVID-19 vaccines. As expected, aggregate COVID tailwind contributions declined sequentially reflecting a decline in revenues from diagnostic testing. We continue to expect COVID-19 tailwinds of around $400 million for the full year compared to approximately $250 million to $300 million in 2020. Adjusted EBITDA in the quarter was up 26% reflecting strong top line growth, favorable mix including nearly 20% growth in sales of proprietary materials and consumables, and outstanding execution enabled by the Avantor Business System. Despite ongoing inflation in excess of historical trends, across a number of cost categories including raw materials, third-party products, transportation, and wages, we leveraged our ABS toolkit to expand EBITDA margin by approximately 180 basis points. Adjusted earnings per share grew more than 48% reflecting the strong EBITDA growth along with lower interest expense and a lower income tax rate. We generated $229.3 million in free cash flow in the quarter, more than 100% of adjusted net income, while at the same time doubling our CapEx investment over the prior year to support our growth initiatives. Our adjusted net leverage ended at 3.5 times adjusted EBITDA down 0.3 times from the second quarter, reflecting our strong cash flow and sustained traction in deleveraging. The funding of the Masterflex transaction will obviously increase leverage in the fourth quarter, but we fully expect that our strong cash flow profile will have us within our targeted leverage range of 2 times to 4 times adjusted EBITDA by the end of 2022. In summary, our third quarter financial results reflect the strength and relevance of our portfolio, our integrated offering, and exposure to the biopharma space, and our unwavering focus on execution supported by the Avantor Business System. I am proud of our team for delivering another strong quarter and confident in our outlook for the fourth quarter and beyond. With that, let me turn it over to Tom to walk you through our results in more detail.

Thank you, Michael, and good morning, everyone. I'm starting on slide 6. As Michael noted, organic growth was 10.2% this quarter, leading to year-to-date organic growth of approximately 15%. Our core organic growth rate, meaning organic growth less the estimated COVID tailwind was nearly 9% and improved nicely from the approximate 2% core organic growth rate in the third quarter of 2020. Proprietary materials and consumables grew nearly three times the rate of third-party materials and consumables, which as you know drives a favorable margin mix for the enterprise. From a regional perspective, Americas, which represents approximately 60% of annual global sales, achieved 9.1% organic revenue growth driven by double-digit sales growth in biopharma production offerings, lab consumables, biomaterials, and procurement services. Biopharma production sales grew about 30% in the Americas, driven by sales of chemicals and single-use consumables, including those to support COVID-19 vaccine. We also achieved record sales of proprietary silicone formulations for our biomaterials platform as demand for elective procedures fully recovered in the quarter. Europe, which represents approximately 35% of annual global sales, achieved 10.9% organic revenue growth driven by double-digit growth in lab consumables, biopharma production offerings, and biomaterials. Growth in COVID vaccine-related revenues were offset by anticipated declines in revenue from diagnostic testing, resulting in limited net COVID tailwinds in the quarter. EMEA, representing approximately 5% of annual global sales, achieved 16.4% organic revenue growth, which included a modest offset from COVID headwinds. Growth was driven by especially strong demand for our proprietary offerings in bioproduction and semiconductor manufacturing. Let's move to slide 7, which shows our organic revenue growth by end market and product group for the quarter. Biopharma, representing approximately 50% of our annual revenue, experienced high-teens organic growth in the third quarter, including roughly 26% organic growth in bioproduction, driven by exceptional growth in single-use consumables as well as double-digit growth in production chemicals. Demand patterns continue to be impressive, and open orders in biopharma production are now 65% higher than the beginning of the year. On the research side, the biopharma end market grew in the mid-teens, driven by lab consumables and supported by customer reopening. Healthcare, which represents approximately 10% of our annual revenue, experienced mid single-digit organic revenue growth, driven by a record demand for our medical-grade silicone offering in the elective surgical market, offset by lower COVID diagnostics testing sales. Education and government, representing approximately 15% of our annual revenue, experienced low single-digit organic revenue declines in the third quarter. Our education market experienced a low single-digit growth driven by ongoing recovery in university research labs and K-12 activities. Government sales declined double-digits on lower sales of COVID-related test kits and personal protective equipment. Advanced technologies and applied materials, representing approximately 25% of our annual revenue, achieved high single-digit organic revenue growth, driven by broad-based growth in lab products sold for research and QA/QC especially in Europe and EMEA and in proprietary chemical formulations for semiconductor manufacturing. By product group, as I mentioned earlier, our proprietary materials and consumables offerings achieved high-teens organic revenue growth driven by strong demand for our biopharma production materials and single-use consumables as well as by our biomaterials and electronic chemicals platforms. We also achieved double-digit growth in our equipment and instrumentation portfolio with good growth in both Americas and Europe against a favorable prior year comparison. Services had a mid single-digit growth quarter, driven by strong global lab and production services. Let me turn to slide 8 for key financial performance metrics. We achieved approximately 26% growth in adjusted EBITDA and 180 basis points of margin expansion to 19.6% from 17.8% in the comparable prior period. The margin rate expansion was driven almost entirely by gross margins, which expanded to 33.6%. We continue to generate strong productivity, sound inflation management, and a favorable mix, as our higher-margin proprietary materials and consumables once again achieved superior growth rates relative to those of our third-party materials and consumables. Adjusted earnings per share were $0.35 up 48%, reflecting ongoing operating performance and reduction in interest expense from our deleveraging and debt refinancing and reprising activity. Although our income tax expense was higher than the prior year, we did have an effective tax rate of approximately 19% in the quarter, reflecting a catch-up to the now expected 22% rate for the full year, driven by the impact of higher-than-expected deductions as well as U.S. tax credit planning. Our tax rate for the full year was previously expected to be 23%. Free cash flow, a non-GAAP financial measure which we define as cash from operations, excluding one-time acquisition costs, less capital expenditures was $229 million, compared to $266 million in the comparable prior period. The decline was driven by higher cash taxes reflecting higher income and the expiry of Cares Act provisions, working capital investments to support our growth, and more than $30 million in capital expenditures in the quarter, mostly related to growth-driven initiatives more than double the 2020 CapEx. We continue to forecast $850 million of free cash flow for the full year. Moving to slide 9, as Michael indicated, we are raising our guidance for the year to reflect strong year-to-date performance, stable core end markets, and confidence in the fourth-quarter outlook. This represents our third raise to the annual guidance this year. We now expect organic sales growth of approximately 10% to 11% for 2021, which includes approximately 2% from COVID-19 tailwinds. We continue to expect roughly $400 million in COVID-related revenue for the full year which includes modest COVID-19 organic revenue headwinds in the fourth quarter, which are expected to continue into 2022. The evolution over the course of the year to a higher proportion of vaccine-related tailwinds and a lower proportion of diagnostic testing tailwinds has also played out as expected. Layering in projected impact from M&A of approximately 2.5% and from FX of approximately 2%, we are estimating total reported growth of approximately 14.5% to 15.5% for the full year. We're increasing our full-year adjusted EBITDA margin expansion guidance from 150 basis points to more than 170 basis points, reflecting our strong year-to-date results, continued core business momentum and a modest benefit from Masterflex. The margin accretion from Ritter was already reflected in prior guidance. We now anticipate adjusted earnings per share growth of approximately 55%, up from our previous guidance of approximately 50%. This new EPS growth estimate incorporates the impact from M&A including Masterflex and an incrementally lower income tax rate offset by higher interest expense and a slightly stronger U.S. dollar, adversely impacting foreign currency translation. We are maintaining our full year free cash flow guidance of approximately $850 million which we raised at the end of the second quarter by $50 million. We expect the EBITDA upside reflected in our earnings and free cash flow guidance to be offset by higher investments in working capital and capital expenditures to support our growth initiatives. One final comment regarding leverage, as noted earlier in the presentation, we ended the third quarter at 3.5 times adjusted EBITDA an improvement from 3.8 times at the end of the second quarter. The net debt in the 3.5 times adjusted EBITDA calculation conservatively excludes the $967 million in net proceeds we received from the Masterflex-related equity issuance in September. Upon the close of the Masterflex transaction, we expect leverage to be approximately 4.7 times adjusted EBITDA. We are confident in the attractive cash generation capability of our business model and are committed to be within our targeted two to four time adjusted EBITDA leverage range in 2022. This concludes my prepared remarks. I'll now hand the call back over to Michael.

Thanks Tom. I'm now on slide 10. The relevance of Avantor's Business Model and the importance of our mission of setting science in motion to create a better world is evident in our strong year-to-date performance and the overall momentum in our core business. We continue to execute well as evidenced by our margin expansion, EPS growth, and free cash flow results. We remain committed to our growth strategy, including the ongoing integration of Ritter and RIM Bio and soon Masterflex. We will continue to focus on biopharma as a key growth driver for our company and will support our customers and ongoing investments in manufacturing capacity. We're also committed to advancing our sustainability initiatives through our Science for Goodness platform. As we look ahead, we are well positioned for continued growth across each of our end markets and expect to deliver another solid year in 2022. The role of Avantor's products and services in enabling scientific breakthroughs has never been more important. I want to thank you for your interest in Avantor and for your ongoing support. I will now turn it over to the operator to begin the question-and-answer portion of our call.

Thank you. Your first question is from Tycho Peterson from JPMorgan. Your line is now open.

Hey. Good morning. Tom, I'd like to start with the EBITDA margin expansion, which was certainly impressive. You talked about inflation management. Can you maybe just talk on how much of that gross margin expansion, which drove most of it was from pricing versus mix and maybe some of the productivity initiatives?

Yes, Tycho. Thank you for your question. I believe you're asking about the growth in EBITDA margins, which increased by approximately 180 basis points, primarily due to gross margin expansion. This growth was a balanced mix coming from three key factors. The favorable proprietary mix has been a significant contributor, as the growth in our proprietary products was nearly three times that of third-party products, though third-party growth was still solid in the mid-single digits. Overall, the sales mix was favorable. Additionally, we effectively managed pricing over cost of goods sold, which helped enhance our margins. While cost of goods sold and inflation had a slight impact, we successfully offset these challenges through commercial strategies and other means. Lastly, our ongoing productivity initiatives, which leverage increased volume, also played a crucial role. I would highlight that these three factors were equally significant in the growth of our gross margin.

Okay. And then for Michael, just curious if you could comment on Ritter and RIM performance, I know M&A was 3% to 3.2% or so for the quarter, but how has the integration gone in those two? And then separately, on O&T, you noted launching a handheld scanner and sequencer. I'm just curious to hear a little bit more about the strategy around that? Thanks.

Thanks, Tycho. Obviously, early days for both the RIM and Ritter acquisitions. Integrations on both fronts are going as expected. So, I think we've got a pretty low playbook by now for driving integrations of these acquisitions, and certainly excited by the momentum we have in integrating the new capabilities into our channel and presenting those offerings to our customers. In the quarter, I think, both expected roughly in line with our expectations, with perhaps a similar trend in the COVID exposure, which is somewhat modest for Ritter as in our own business, as we saw somewhat of a sequential decline in revenues into COVID-related applications for Ritter, but the German business is performing ahead of plan. We're excited about the momentum we have in positioning those products in our channel. Similar to our other proprietary offerings, these are specification driven products, which require our customers to qualify these products into their processes and applications and our teams are busy in sampling and qualifying these opportunities and we have a pretty full pipeline that we're working on. So pretty excited about where we're at with both of those acquisitions.

The second thing O&T?

The second question is a great example of the strength of our channel and the opportunity it provides our third-party partners to showcase their innovations. There is significant excitement surrounding the technology that enables sequencing on the desktop, which marks a major advancement in innovation and technology. Our access to labs globally underscores the effectiveness of our model and illustrates our partners' interest in utilizing our network to introduce their content along with our other capabilities. We have seen substantial early momentum since the launch through our channel. This highlights our commitment to innovation, whether it comes from our internal research and development or from the innovations we introduce from our partners, demonstrating the vital role we play in the innovation ecosystem by delivering relevant technologies to our customers.

Understood. Thank you.

Your next question is from the line of Derik de Bruin from Bank of America. Your line is now open.

Hey, good morning.

Hi, Derik.

Hey, I know you're not providing specific guidance for 2022, but could you clarify something? When you mentioned that your plans for 2022 align with your long-term objectives, does the 4% to 6% target include the impact of COVID, or is it based solely on the core business, considering that we expect COVID-related effects to decrease in 2022 compared to 2021? I would appreciate some clarification on that.

Good place to start. I think the way you're thinking about it is spot on. As we talked about at Investor Day, we expect next year to be in line with our long-term targets of mid-single-digits and that would be inclusive of the COVID headwinds that we would expect next year. We'll get more specific when we do the guide in January. But I think probably not a bad way to model at a roughly 2% headwind for COVID in our business next year and that would be reflective of ongoing durability of the vaccine revenues that we enjoy today and sequential downturn decline in contributions from PPE and diagnostics. And in our mid-single-digit outlook, we feel confident that we can absorb the headwinds that this would reflect and deliver against our long-term targets for next year. But we'll get a little bit more specific for you as we move into January.

Great. That's quite optimistic. In that regard, are you facing any issues with supply chains or challenges with your suppliers in delivering products? Are there any shortages or weaknesses in the channel?

Derik, I'd say that there are, but I wouldn't necessarily say that they are any different or more acute than we've seen throughout the year, and it seems to move from different categories. We're certainly seeing some improvements in things like PPE availability, and some of the plastic wear that has been short for the better part of 18 months. We're starting to see some improvements in availability of supply in some of those categories. Some of the other categories, like some of the resins, for example that go into some of the single-use offerings which have been persistently growing well into the high double-digit levels, continue to be constrained. So it's a bit of a balance, but I wouldn't say it's much different than we've experienced throughout the year, and the teams are doing a great job managing through that leveraging the ABS toolkit problem solve on a real-time basis, and keeping things moving. But certainly, there are constraints and whether they're product availability, or certainly some of the labor constraints that everyone is facing in the US those are certainly in our business today, but not at any different levels than we've seen from previous quarters.

Great. And then just one housekeeping question for Tom. What's the – what are your expectations on share count for Q4 full year just given the equity raise?

Yes. As you know, from the equity raise that we did in mid-September related to the Masterflex transaction, which raised roughly $1 billion at $42 share price, the shares that came with that, including the exercise of the green shoe, because we were oversubscribed by about five times on the offering, came in about 23 million, 24 million shares on that. So as we reset 2022, Derik, what we're going to do is reset this adjusted share count. As you know we've been – we've conservatively maintained an expanding number for the adjusted share count that includes the presumed conversion of our mandatory convertible preferred stock. So even though the share count has averaged around 5.80, 5.90, we've for reporting purposes to all of you in our discussions have assumed the conversion of that mandatory convertible. So that is what's behind the 6.42 that we've used. But we'll adjust the 6.42 to reflect the issuance of the shares from Masterflex, as well as other minor changes in share count that have happened. Of course, you can always see the base outstanding shares, the diluted outstanding shares on a GAAP basis in our 10-Q.

Thank you.

Your next question is from the line of Vijay Kumar from Evercore ISI. Your line is now open.

Hey, guys. Congrats on the print, and thanks for taking my question. Michael, just to clarify on the prior question from Derik, the fiscal 2022 commentary was inclusive of two points of headwind from COVID, so the assumption is your base business for next year excluding COVID is tracking – or I shouldn't say tracking perhaps the expectation is high single digits?

Yeah, happy to provide some clarification there, Vijay. The mid-single-digit guide that we – or target that we have outlined there at our Investor Day, as we said then, and reiterate again today, certainly is inclusive of how we see COVID playing out next year, which would include roughly two points of headwind for us. And I think consistent with how the business has been running over the last two or three years, I think the growth that you're talking about there for the core business is in line with what we've been delivering each of the last several years, including this year. So, not a bad way to think about it.

Got it. Considering the impact of COVID, we are likely at a figure of five, and excluding those impacts, it's around seven or the base level. Regarding the COVID tailwinds, can you remind us of the former range of 350 to 450, as we're now adjusting that to 400? What portion of that is from vaccines and what portion is from diagnostics and others for fiscal 2021? Additionally, should we expect vaccine tailwinds to be stronger in fiscal 2022, similar to what other companies are experiencing?

Yes. So, if you look at the mix that we've been talking about, I think it's playing out in line with what we've described roughly 40% to 50% of our tailwinds are vaccine. Roughly 40% to 50% are diagnostic testing and then the balance is PPE. And that is kind of the aggregate view across the year. Obviously, as we move throughout the year, the contribution from vaccines becomes the majority of the benefits that we're getting here. And as we've said before, we expect that to be durable and continuing to increase as we move into next year both as production internally ramps as we bring on some of our capacity expansion as well as just more capacity for vaccine production being available globally as we move forward and in line with our expectations, diagnostic testing and PPE we would expect to continue to decline over time.

Got you. And Tom, just on the share count, just to be clear what you're saying is base of 6.40 plus another 23, so that's around mid-6.65, something like that. Is that what you're pointing to on share count?

Yes. As you know, Vijay, we've used 6.42 since the IPO. And since the IPO, there have been other equity transactions minor ones like option exercises and restricted stock units that we haven't continued to update the 6.42. We've kept it flat just for simplicity purposes, but we'll be baseline the 6.42 to reflect the Masterflex as well as to reflect any other transactions that have happened. Of course, you can always see the base outstanding shares, the diluted outstanding shares on a GAAP basis in our 10-Q.

Thanks guys.

Your next question is from the line of Dan Brennan from Cowen. Your line is now open.

Thanks for taking the question. Just wanted to start off on biopharma, particularly for bioproduction, so obviously solid growth revenues and orders. Can you just give us a flavor for like ex-COVID what that number looks like both on the revenue and order side? And just give us some color on what you're seeing in that business?

Yes, you're correct in that, so we continue to see great momentum in biopharma end market at the R&D portion of our core business as well as at production. And just to remind you biopharma is roughly 50% of our overall revenue and about two-thirds of our revenue is captured in the R&D space. And we see continued momentum there as labs start to return to more normalized operations higher levels of activity driving strong growth in that part of the business then roughly one-third of the platform is our offerings into bioproduction, where we continue to see very, very strong growth as is reflected in our prepared remarks, just under 30% growth in the quarter with a very, very strong order book. Order book continues to grow. As we've said in previous quarters we're sitting on roughly a year of open orders for that platform, which is a bit unusual or quite unusual and it continues to grow day by day. Interestingly, the makeup of that order book continues to be dominated by our core business. I would say over 80% of the order book is in fact related to our offerings into our core monoclonal antibody cell and gene therapy business excluding COVID. So, great momentum in both the core and obviously we're well positioned to capture the ongoing benefits of COVID vaccine exposure. But the business overall is quite healthy and contributing at a high level both organic revenue growth as well as margin expansion given the proprietary offerings that we have in the production portion of that platform.

And Dan, I would also add to what Michael said. If you look at the high teens growth for biopharma in the quarter, two-thirds of the growth was the base business and roughly a third was driven by COVID.

Great. Thank you, Tom. And maybe just one on kind of education and government. Obviously, the government looks like it was under pressures, just given some of the COVID kind of natural slowing. On the education side, just wondering what the outlook is there, given the funding environment juxtaposed against probably some near-term pressure from lab access, just as we're in the fourth quarter and we're looking ahead, would that be a nice tailwind as we get into 2022, maybe as that lab pressure alleviates?

So the education government portion of our business is approximately 15% of our revenue with two-thirds of that being in education, the other third being in government. Government was certainly a headwind for us, really reflecting the strong COVID-related revenues we enjoyed in the prior year period for things like PPE and diagnostic testing that didn't repeat in this particular quarter. On the education front, while there's certainly some level of COVID headwind on a year-over-year basis in the quarter reflected there, we do see continued improvement in lab utilizations. And at the university level contributing to what I characterize as kind of low single-digit growth for that part of the platform. And then in the science education portion of our business, which is roughly 2% of that overall education and government platform, continues to be a bit sluggish. We haven't really seen much of a pickup this year in line with what we normally expect for curriculum deployment at K-12 districts across the United States. So the next opportunity is probably there for that recovery will be going into next year. But we're, I think, pleased with how things are developing in education portion of that business. And the government portions, they're running in some pretty tough comps just given the role that governments around the world played in deploying COVID-related offerings in prior year periods.

Great. Thanks, Michael. Just one housekeeping item. Just what's the base ex-COVID organic for 4Q that's implicit in the new 10 or 11 full-year range? Can you just give us that number? Just to make sure we're doing that right?

Yes. For Q4, I think it works out to a 3.5% tailwind for the quarter.

You recall, quarter of 2020 was close to our high mark in terms of COVID-related revenues. As Michael had mentioned, while the vaccines continue to have durability and we'll have durability the next year, the impact in the Q4 starts to turn a bit because of the reduction in the peak of diagnostic testing as well as PPE usage.

Got it. Thank you.

Your next question is from the line of Jack Meehan from Nephron Research. Your line is now open.

Thank you. Good morning. I wanted to start, just get a little bit more color on Ritter. Do you feel like they're still on track for $225 million of sales this year? I look at the M&A contribution of $50 million or so. It was a little below what I was thinking. And then one other Ritter question, it looks like most of the M&A came in Europe, just thoughts on geographic expansion.

Yes, thank you for your questions, Jack. It's great to hear from you this morning. As I mentioned earlier, we remain very excited about Ritter. We are just a couple of months post-acquisition, and the integration is progressing well. Reflecting on our comments during the acquisition announcement regarding market exposure, we acknowledged a small exposure to COVID-related applications, estimated to be in the 10% to 20% range. Initially, we anticipated this would decline around 2022, but it has happened a bit faster than expected. However, the core business remains strong, allowing us to enhance our synergy capture. This also means we can allocate more resources to provide samples and initial stock volumes for our customers. Our teams are actively engaging with our healthcare and biopharma clients worldwide. As I mentioned earlier, our products require customer qualification in their processes and applications, and our teams are focused on sampling and qualifying these opportunities, resulting in a robust pipeline. Overall, we're quite optimistic about the progress of both acquisitions.

Got it. That makes sense. And then just another question on 2022, in your initial planning, just any thoughts around whether the historical algorithm of proprietary growth outpacing third party should hold. There's obviously a lot of moving parts. Just trying to think about the implications for margin expansion.

I think we're comfortable with our historical continuing of mid-single-digit organic growth. Conversion of revenue to EBITDA in this 1.5 to two times range that we typically see and that is obviously driven in part by very, very strong proprietary growth with the investments that we've made this year and the momentum that we have in our proprietary offerings. We don't see any reason why that wouldn't play out next year as well.

Great. Thank you.

Your next question is from the line of Tejas Savant from Morgan Stanley. Your line is now open.

Hey, guys. Good morning, and thanks for taking the questions here. Michael, I was just curious on Jack's earlier question as well on margins for 2022, can you comment on your ability to – or rather your confidence in passing through inflation on the distribution side of the business, particularly given rising freight costs? And on a somewhat related note, are you guys seeing any sort of deterioration in your on-time delivery metrics at all?

Yeah, great questions. On your first point around inflation management, clearly, the team has done a nice job managing that this year. And as Tom indicated, inflation didn't just show up in the third quarter. It's been higher than historical trends for the better part of the year and as well as on the raw material side or on the wage front. We've certainly seen escalations there above historical levels. And you see the execution of the team and the action the team has in offsetting these through a number of means, including pricing as evidenced by our strong margin expansion this year. Typically, this time of the year is quite busy and the teams are focused on driving price adjustments into the market going into the New Year. And I would say, one of the differences this year compared to previous years perhaps is the process has started probably a little bit earlier. And you see it both from our suppliers as well as the market at large here, most folks getting – trying to get ahead of this and get prices effective as early as they can to reflect the rising cost environment that we face. And so we're very active in communicating with our customers about 2022 pricing as well as presenting, I think, a number of alternatives here and really offering choice, which is one of the strengths of our business model here is where customers have flexibility on branding, being able to take advantage of the flexibility that our channel provides in trying to offset some of the inflation. But net-net, price increases will be higher this year than maybe historical to reflect the environment or going into next year excuse me to reflect the inflationary environment that we see. But we're in conversations with our customers and I think at this stage are comfortable that just given the macro backdrop that we're going to be able to manage the inflation as we normally do.

Got it. And on my question on delivery metrics?

Yes. So, certainly the supply chain has been strained over the last 18 months given the rapid run up in demand. I wouldn't say necessarily that we've seen a deterioration of our on-time metrics where we are seeing the impact and is the lead-times for many of our products have been pushed out to reflect the constraints. And so against maybe our historical lead-times certainly not able to keep pace with those levels. But with the increased lead-times that we have for most of our products which gets reflected in our order book then the supply chain is holding up well.

Got it. And one final one on the single-use capacity expansions you've announced recently. Obviously, the Netherlands site is very recent but can you give us a sense for capacity utilization at in Massachusetts and your other facility in North Carolina?

Yes great questions. When you look at what we have done here from both kind of an organic expansion in both North Carolina as well as the Devens Massachusetts site together with the launch of the greenfield site in Europe and the acquisition in China, we've increased our clean room capacity by more than fourfold this year which is going to give us a lot of flexibility here to recognize significant growth over the next couple of years. But it was needed we're our backlog has been growing in single use. The demand for our technologies is significant. And so our factories are quite busy. And when we look ahead here when we talked about the Masterflex acquisition in our prepared remarks that's going to be a nice complement to our existing single-use offering and give us a complete end-to-end integrated solution for aseptic fluid transfer technologies. And there are some complementary capabilities on the assembly side of that business that we will have the opportunity to incorporate the Masterflex clean room capabilities into our own footprint and then integrated in with the pumping and tubing capabilities that Masterflex brings. So, we're super excited about the developments of our single-use business the capabilities that we'll have and the offering that we'll give to the market here. But yes no doubt our factors are pretty good.

Got it. Appreciate the time this morning.

Your next question is from the line of Patrick Donnelly from Citi. Your line is now open.

Two questions. Maybe just on the M&A side obviously a little early with Masterflex it and closing. But Tom you talked a little bit about where the leverage is going to be after this deal where you're heading next year. I mean how are you guys thinking about the activity? Is there a certain threshold where you want to be below before you look at the next deal? And maybe just talk a little bit about the pipeline how active things are for you right now?

Yeah. Good morning Patrick, and thanks for the question. The – as I said in our prepared comments, when we close MasterFlex, which we expect it to be really any day now, that will obviously take our leverage up a bit. I think of it as the 4.5% range. I think I said 4.7% in my prepared remarks. But it's in that range. We believe that very rapidly as we demonstrated the last three years, our cash flows will enable us to take a full turn off of that in a year or so. So, if you think of us as less than 4% or closer to 3% by the end of 2022, we're squarely in the middle of our targeted leverage range of two to four times adjusted EBITDA from a debt perspective. And when you look at that and look at where we were at the beginning of this year, we're roughly four times and we're able to deploy capital of $4 billion and get ourselves back to acceptable leverage range or targeted leverage range. We feel like we're in the same boat. We're not in a much different position in terms of our M&A opportunities. And with that said, the types of things we're looking at are very consistent with what we've talked about before. We talk about proprietary. We talk about some of the proprietary spaces, particularly in biopharma production, some of those unique lab workflows as well as the service business, all those would be attractive areas we want to invest in. But obviously, we're going to do it in a disciplined way. We're not in a hurry. We want to achieve returns that are attractive to our shareholders and give us accretion on the top line as well as on our margin rates and keep up on the cash flow. So, I think it's full steam ahead, but with the idea that we're fully focused as well on getting to our stated target leverage levels between two and four times EBITDA.

Understood. Okay. And then Michael, maybe just on the Advanced Technologies and Applied Materials, a pretty nice result there. Can you just talk through the more industrial pieces? And I know obviously, not the biggest piece of it. But are you seeing any difference in geography in slowing in kind of those core industrial markets? Maybe just an update on what you're seeing out there?

Yeah. No, we were pleased to see the momentum that we had in that business continuing to build. We had a second consecutive quarter here of high single-digit growth. And I would say, looking at the trending as we've moved through the year, we see nice progression in all three regions of the world. And maybe most notably, we saw a nice uptick in the EMEA region in the third quarter, maybe to call out there. But I would say the progression in Europe and the Americas was in line with kind of the sequential improvement that we saw. In particular, out here, obviously, the semiconductor space gets a lot of attention at a macro level, just given the chip shortage and the fabs are producing at record levels, and that's having a nice impact on the formulations business that we have in support of wafer manufacturing really around the world, but especially in Asia and in the US. So good backdrop, I would say, positive fundamentals for us overall there.

Great. Thanks, guys.

Thanks.

Your next question is from the line of Catherine Schulte from Baird. Your line is still open.

Hey, guys. Thanks for the question. I guess first on proprietary materials and consumables. You had another strong quarter here with high-teens growth. Can you just break that down between COVID versus core and kind of how you think about the long-term growth rate for that side of your portfolio?

Thank you for the question, Catherine. Regarding our COVID offerings, approximately 40% to 50% are related to vaccines, which are almost entirely proprietary. The remaining 40% to 50% consists of diagnostic testing, which includes a larger proportion of third-party components, though there is some proprietary content as well. When we consider our overall proprietary growth, the high-teens growth we mentioned was likely influenced by COVID to a degree similar to the overall growth rate of 10.2%. I would estimate this to contribute roughly a couple of percentage points.

Okay. Great. And then maybe just on the guide you talked about now assuming some Masterflex contribution in there. I guess what are the timing assumptions around the deal close and expected revenue contribution in the fourth quarter? It seems like maybe somewhere around $40 million but just curious to get your assumptions there.

Catherine, have you been getting inside information here? You're pretty spot on in terms of what we expect for the fourth quarter. That would assume a very imminent close. So you can think of it as roughly two months worth of revenue. And that's pretty much in line with what we've talked about. I think you probably calibrated it based on what we talked about the size of Masterflex. So yes, it will be taking away pretty quickly here and contributing in that magnitude. As you know the margin rates are quite attractive for us certainly accretive to the bond term margin rate. We're looking forward to good impact starting in the fourth quarter.

Great. Thank you.

That concludes our Q&A for today. I will hand it over back to our presenters for closing remarks.

Thank you again for your participation in our call today everyone. As we close I want to express my continued gratitude to our associates around the world who are working hard to deliver values and serve our customers each and every day. The resolute and steadfast support of our customers is certainly critical to our mission and our long-term growth strategy and our overall success. I'm really excited about our future and we're looking forward to updating you when we get an opportunity to meet up back. And until then take care and be safe everyone. Thank you.

And with that this concludes today's conference call. Thank you for attending. You may now disconnect.